J Med Microbiol International Journal of Systematic and Evolutionary Microbiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hospenthal, D.
Right arrow Articles by Rogers, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hospenthal, D.
Right arrow Articles by Rogers, A.
Agricola
Right arrow Articles by Hospenthal, D.
Right arrow Articles by Rogers, A.

The Journal of Medical Microbiology, Vol 30, Issue 3 193-197, Copyright © 1989 by Society for General Microbiology

JOURNAL ARTICLE

Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to Candida albicans

D. Hospenthal, K. Gretzinger and A. Rogers
Department of Botany and Plant Pathology, College of Human Medicine, Michigan State University, East Lansing 48824.

Survival of mice infected with an intravenous injection of Candida albicans was observed in a short-term (21-day) survival study. Concentration of C. albicans in the kidneys, liver, and spleen was determined at various times. The effects of treatment with the commercial formulation of amphotericin B (fAMB), liposomal amphotericin B (LAMB), and liposomal amphotericin B bearing external antibody specific for C. albicans (LAMB-Ab) were compared. In single intravenous treatment dosages of 0.6 mg of amphotericin B/kg, the liposomal forms of the drug (LAMB and LAMB-Ab) enhanced the percentage survival and mean survival time of mice in comparison with those treated with the unencapsulated antifungal compound, fAMB (p less than 0.03 and p less than 0.001, respectively). LAMB-Ab, at this dosage, produced an increase in the survival (p less than 0.007) of mice over that produced by LAMB. LAMB-Ab treatment caused a greater than 3-fold increase over fAMB. The percentage of LAMB-Ab-treated mice which survived for 21 days was almost double that of the LAMB-treated mice. The increase in survival following this treatment did not, however, lead to the eradication of C. albicans in all mice which survived to the end of the experiment.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 1989 Society for General Microbiology.